Current Status of ABL Tyrosine Kinase Inhibitors Stop Studies for Chronic Myeloid Leukemia

Stem Cell Investigation
doi 10.21037/sci.2016.07.08
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AME Publishing Company

Related search

Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Incidence and Outcome of BCR‐ABL Mutated Chronic Myeloid Leukemia Patients Who Failed to Tyrosine Kinase Inhibitors

Cancer Medicine
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2019English

Complications of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia - Chronic Phase

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2019English

Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal of Haematology
Hematology
2019English

Future Perspectives of Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia

Chemotherapy: Open Access
2017English

Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

International Journal of Clinical Pharmacology & Pharmacotherapy
2018English

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group

Cancer
Cancer ResearchOncology
2018English

Preventing and Managing Cardiovascular Toxicities of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Cancer therapy & Oncology International Journal
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy